Founded in 2015, Secarna Pharmaceuticals entered the antisense drug discovery and development space with the goal of addressing high unmet medical needs using a never-before-seen artificial intelligence (AI)-powered platform. It is designed to select and synthesize antisense oligonucleotides (ASOs) against challenging or historically undruggable targets across indications.
Lucie Ellis-Taitt Test Article
Secarna Addresses Undruggable Targets With Antisense Platform
Listen to this article
Exec summary testing space - June 2024.
Candid conversations with C-suite leaders.
More from Leadership
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
More from Growth
• By
Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.
• By
The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?
podcast
• By
Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.